Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I think there is no one more disheartened about this fact than Dr Von Hoff. In fact, maybe Dr Lohr is because they have both dedicated their life's work to helping patients with PC. BTW, if you weren't aware, Ken Waggoner's father died of pancreatic cancer. He seems pretty motivated to me to improving these results as well.
I think this "consolidated therapy" is truly a game changer for all stakeholders. In a little while, a huge amount of progress will be made and I believe Cell in a Box technology will be the catalyst for new hope for PC patients and those who love them...
Well, Ken told us last year they were successful and then they did 2 follow-up studies which they also told us were being done to better define parameters for the upcoming trials. We just got a taste today of what they decided and it actually saves us money to go from doing 3 clinical trials to 2. We have assembled a winning team. KW certainly knows what he is doing.
Nice find!
It sounds to me efood like we have gone from 3 to 2 trials. Makes sense to include pain associated with PC in the 2b. However, the ascites could potentially treat all abdominal cancers. Like you said, they didn't say but I am thinking that trial is too big to include in the "unmet need" need trial and we just might do it for not only patients who have PC but for patients with malignant ascites regardless of the source.
Pretty cool the way they are unveiling the plan...
Great catch MeM. It makes total sense to do it this way especially if we are partnering and not going "head to head". And Dr Von Hoff is a Celgene consultant... And he called us... Might have been part of the plan all along...
Yep, we are very possibly in some entities pipeline as we speak... :)
efood, I think you are dead on. I have watched this stock for less time than you but everything I have seen over the past 20 months supports your theory... JMO
And also why it's good we now have a new transfer agent, ASI who also services Fortune 100 companies and buyins is now monitoring our trades....
We have a great management team for sure...
http://www.thestreet.com/story/13213290/1/pharmacyte-biotech-appoints-american-stock-transfer-as-new-stock-transfer-agent.html
http://globenewswire.com/news-release/2015/10/01/772738/0/en/PharmaCyte-Biotech-Retains-Industry-Expert-to-Monitor-Short-Sellers-and-Market-Makers.html
http://www.buyins.com/brochure.pdf
Either they like pennies or they want to keep it down...
JMO
Yep, be glad when they are bought out...
PMCB is showing it's all real. But if some can be persuaded to think otherwise, it seems to be of a benefit to others.
It's like being in a deliberation room. If there has been enough doubt raised, maybe some will jump ship before the verdict is even in. Craziness, IMO..
I am firm in my belief on this one, no doubt...
And this was reported after the first clinical study...
"Preliminary data analysis suggests that treatment with Nuvilex's live-cell encapsulation technology, Cell-in-a-Box® plus ifosfamide, produces a significant survival advantage as compared to non-treated control animals. Nuvilex's treatment appears to be at least as good as cisplatin, the current standard of care for ovarian cancer. However, when the encapsulated cells plus ifosfamide were used in conjunction with cisplatin, the survival rate was greatly enhanced. The final data analysis will be released in the future."
http://globenewswire.com/news-release/2014/11/19/684617/10108949/en/Nuvilex-Announces-Preliminary-Data-From-Preclinical-Study-of-Effects-of-Its-Pancreatic-Cancer-Treatment-on-Ascites-Fluid-Formation.html#sthash.y2R72xy4.dpuf
I think you are absolutely right, Pete. There is a strong base of longs here and it may be a question some have even posed to him. Ken has always been good about keeping us informed...
Enjoy Octoberfest and thanks for all you do, Bio... Have a great weekend!
Nice to see them jumping in. Just hope they understand this is a biotech and although we can have gains for each accomplished milestone, there can be a lag between those milestones which may mean watching and waiting and opportunities for folks to try and talk the price down.
Understanding how an R&D biotech works on the OTC will save a lot of grief... Especially if you are investing for long-term gains...
You are pretty good. MM for you... Oops, guess I already did that. :)
Trently, I think you have a great point. This company has the potential to do things never before accomplished. I feel so blessed to be a part of this biotech journey. And I found this company by just looking at posts by someone I liked on another board. How fortunate for all of us who are able to see the monumental possibilities here!
We use a lower dose as well. With the targeted treatment, a higher dose is not required and in fact, the lower dose was more effective with CiaB treatment...
"If successful, we believe that PMCB could emerge as the universal therapy or “go-to” treatment for multiple cancers."
Awesome statement and full of merit, IMO... We will know soon enough... Trials should prove this to be true.
Also like to hear this...
"This multi-site trial will combine Cell-in-a-Box® with a low dose of ifosfamide, in an effort to treat patients with locally, advanced pancreatic cancer."
The more patients we are able to treat in a trial, the quicker we can obtain the data needed for FDA approval...
Patience Longs. The noise may get louder, trying to drown out all the good news leading to our success. But those who can withstand these efforts will be rewarded in the long term, IMO.
Best wishes to all who support efforts to get Cell in a Box treatment to patients...
http://www.goldmanresearch.com/201510081041/Opportunity-Research/undervalued-pharmacytes-breakthrough-technology-to-treat-diabetes-and-cancer.html
Good news and I am more inclined to believe the charts now that our volume is not inflated by "fugazi" trades...
Yep, I will have to say that you have very clear vision GC. I think that is exactly why our CEO is so confident. He has already had the conversation... Very clearly...
Welcome aboard! :)
Yes, GC has been on fire lately..
And it does take vision here plus a little personal due diligence to see that this technology can revolutionize treatments for so many illnesses and its potential value for just oncology and diabetes alone is worth billions...
We have also discussed how some root for the company to fail and others can see our success just over the horizon.
Quote...
"I personally don't think we were denied with this most recent application. Most likely we withdrew our application and will reapply at a future date.... The show isn't over yet fros..."
As many have said in the past, all the talk that suggests failure, is just that, just talk. This company will be taking Cell in a Box to market if Ken Waggoner, Doctors Von Hoff, Hidalgo, Gunzburg, Crabtree, Lohr and Salmons have anything to say about it. Btw, key people do listen to what they have to say as is evidenced by Dr Von Hoff's success with the FDA.
I am not betting against these guys or Cell in a Box technology...
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=115619619
"CAR T-cell therapy can cause several worrisome side effects, perhaps the most troublesome being cytokine-release syndrome."
There are enough cancers for many players to be in the game. And it seems we do have something they don't have.. No treatment related side effects...
"Furthermore, no treatment-related side effects were reported with this treatment (CiaB) compared to significant treatment-related side effects with the gemcitabine therapy."
http://globenewswire.com/news-release/2015/09/22/770088/0/en/PharmaCyte-Biotech-Discusses-Pancreatic-Cancer-Treatment-for-Upcoming-Phase-2b-Human-Clinical-Trial.html#sthash.s6GQbhSv.dpuf
No more games... Will make it more difficult to keep the price down...
Dr Gunzburg and Dr Salmons created Cell in a Box. They have more invested in this technology than anyone. If anything, we are helping them to realize their dream... They have been talking up this technology long before we bought licensing rights to it...
Very nice posts today,Runuvi... Thanks.
I agree. Congrats to our management team. I think buyins.net monitoring trade compliance may be making a difference. Nice purchases today. This additional monitoring may be boosting investor confidence...
SILVER SPRING, Md., Oct. 01, 2015 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell in a Box ®, announced today that BUYINS.NET, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has initiated coverage on Pharmacyte Biotech after releasing the latest short sale data through September 29, 2015. BUYINS.NET will monitor the market makers of PharmaCyte Biotech’s stock daily for compliance with fair market-making requirements.
The SEC adopted Regulation SHO in 2005 to update short sale regulation in light of numerous market developments since short sale regulation was first adopted and to address concerns regarding persistent failures to deliver and potentially abusive “naked” short selling. Due to continued concerns about failures to deliver, and to promote market stability and preserve investor confidence, the SEC has amended Regulation SHO several times since 2005 to eliminate certain exceptions, strengthen certain requirements and reintroduce a price test restriction.
Regulation SHO requires bona-fide market-making activities to include making purchases and sales in roughly comparable amounts. The SEC has stated that bona-fide market-making does not include activity that is related to speculative selling strategies for investment purposes of the broker-dealer and is disproportionate to the usual market making patterns or practices of the broker-dealer in that security. Likewise, where a market-maker posts continually at or near the best offer, but does not also post at or near the best bid, the market-maker's activities would not generally qualify as bona-fide market-making. Moreover, a market-maker that continually executes short sales away from its posted quotes would generally not be considered to be engaging in bona-fide market-making.
http://www.otcmarkets.com/stock/PMCB/news?id=115736
So many good reasons to make this move. Nice post...
Very good info. They are on the job. Thanks KW...
They raise money for trials from thier capital so this move actually makes a lot of sense. And, I think LittleRicky may be on to something... Could a potential suitor want us to clean house?
It's good news for all stakeholders...
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=117394605
Good point, Bio...
BUSINESS IS WAR AND YOUR MARKET CAP IS THE BATTLEFIELD
http://www.buyins.com/brochure.pdf
This is such great news. These guys are very determined to get us to human trials and beyond. What a show of commitment to all stakeholders... I am lovin' it!
BUYINS.NET monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze trigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies and comparable valuations.
Thank you, thank you, thank you, Ken Waggoner!
The circumstances are certainly different. We are now a biotech only since 2013. We have never worked with a U.S. based CRO, TD2. We have never had FDA ODD. We have never applied for an IND in the U.S. We have a new CEO since 11/2013 and 2 months later we were contacted by Dr Von Hoff. And now we are looking at treatments for conditions for which there are no treatments, pain associated with pancreatic cancer, malignant ascites and now patients with LAD.
But you should definitely do your own DD. Some folks do like to go back to when we had different business models and if that is significant for you, then it is.
However, I love the rock on which we are now built, Cell in a Box(R) technology. But that is just me and a lot of other longs around here.... Everyone has to follow their own path, nonetheless. And I have been a fan for over 18 months and not deviating from my path...
http://www.pharmacytebiotech.com
Jimmy Joe, I also would like to increase my holding as well. It's bitter sweet in that we are able to purchase shares at such a low price but the lower the pps, the more stress it puts on the stock because of pending trials.
However, the trials are becoming more and more intriguing and appear masterfully planned, IMO...
Love your posts...
Thanks...
Me too... :(
Hey Brian, here is a comforting thought...
"Because someone we love is in heaven, there is a little bit of heaven in our home..."
Go $PMCB!